Abstract
In this review we describe the genes encoding α2δ subunits, their topology and predicted structure. We then review the electrophysiological effects of α2δ subunits. It is clear from most studies that α2δ subunits increase channel density at the plasma membrane, but there is less agreement between studies and between channel subtypes concerning the effects of α2δ subunits on voltage-dependence of activation and inactivation. Most studies agree that α2δ subunits increase the kinetics of inactivation, for a number of different calcium channel subtypes. We also discuss the link between α2δ subunits and disease, particularly in terms of Ducky, the spontaneously occurring mutant mouse strain that has mutations in α2δ-2, and exhibits cerebellar ataxia and absence epilepsy. Finally, we will examine the evidence that α2δ subunits are the site of action of the anti-epileptic, anti-nociceptive drug gabapentin.
Keywords: voltage-dependence, ducky, cerebellar ataxia, epilepsy, anti-epileptic
Current Neuropharmacology
Title: Calcium Channel α2δ Subunits: Structure, Functions and Target Site for Drugs
Volume: 1 Issue: 3
Author(s): Carles Canti, Anthony Davies and Annette C. Dolphin
Affiliation:
Keywords: voltage-dependence, ducky, cerebellar ataxia, epilepsy, anti-epileptic
Abstract: In this review we describe the genes encoding α2δ subunits, their topology and predicted structure. We then review the electrophysiological effects of α2δ subunits. It is clear from most studies that α2δ subunits increase channel density at the plasma membrane, but there is less agreement between studies and between channel subtypes concerning the effects of α2δ subunits on voltage-dependence of activation and inactivation. Most studies agree that α2δ subunits increase the kinetics of inactivation, for a number of different calcium channel subtypes. We also discuss the link between α2δ subunits and disease, particularly in terms of Ducky, the spontaneously occurring mutant mouse strain that has mutations in α2δ-2, and exhibits cerebellar ataxia and absence epilepsy. Finally, we will examine the evidence that α2δ subunits are the site of action of the anti-epileptic, anti-nociceptive drug gabapentin.
Export Options
About this article
Cite this article as:
Canti Carles, Davies Anthony and Dolphin C. Annette, Calcium Channel α2δ Subunits: Structure, Functions and Target Site for Drugs, Current Neuropharmacology 2003; 1 (3) . https://dx.doi.org/10.2174/1570159033477116
DOI https://dx.doi.org/10.2174/1570159033477116 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Expression and Function of Cytochrome P450 in Brain Drug Metabolism
Current Drug Metabolism Molecular Mechanisms Underlying Specificity of Excitotoxic Signaling in Neurons
Current Molecular Medicine Therapeutic Potential of Voltage Gated Calcium Channels
Mini-Reviews in Medicinal Chemistry HHT: A Rare Disease with A Broad Spectrum of Clinical Aspects
Current Pharmaceutical Design Design, Synthesis, Anticonvulsant Activity, Preclinical Study and Pharmacokinetic Performance of N-{[3-(4-chlorophenyl)-4-oxo-3, 4-dihydroquinazolin- 2-yl] methyl}, 2-[(2-isopropyl-5-methyl) 1-cyclo Hexylidene] Hydrazinecarboxamide
Central Nervous System Agents in Medicinal Chemistry Epigenetic Effects Mediated by Antiepileptic Drugs and their Potential Application
Current Neuropharmacology Nitric Oxide: Target for Therapeutic Strategies in Alzheimers Disease
Current Pharmaceutical Design Dissecting the Mechanisms of Thrombogenesis and Atherosclerosis for Neurodegenerative Disorders
Current Neurovascular Research Disorders of Protein Biogenesis and Stability
Protein & Peptide Letters Novel Treatment and New Drugs in Epilepsy Treatment
Current Pharmaceutical Design Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics
Current Drug Safety Pharmacokinetic Studies in Infants Using Minimal-Risk Study Designs
Current Clinical Pharmacology Effect of Nutrient Medium, Phytohormones and Elicitation Treatment on in-vitro Callus Culture of Bacopa monniera and Expression of Secondary Metabolites
The Natural Products Journal Safety Profile of the Newest Antiepileptic Drugs: A Curated Literature Review
Current Pharmaceutical Design Characterization of a New Positive Allosteric Modulator of AMPA Receptors - PAM-43: Specific Binding of the Ligand and its Ability to Potentiate AMPAR Currents
Current Molecular Pharmacology Editorial [ Neuropeptide Y Receptors as Targets in Drug Discovery Guest Editor: Ambikaipakan Balasubramaniam ]
Current Topics in Medicinal Chemistry Physiology and Pharmacology of Two-Pore Domain Potassium Channels
Current Pharmaceutical Design Food Selectivity, Gastrointestinal Symptoms and Urine Organic Acids in Autism Spectrum Disorder: A Pilot Study
Current Nutrition & Food Science New Perspectives on the Structure and Function of the Na+ Channel Multigene Family
Current Medicinal Chemistry - Central Nervous System Agents